Press Release
Jun 9, 2021
Actimed Therapeutics to Present at BioTrinity 2021

London, UK – 15 June 2021. Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, will present at the BioTrinity 2021 Conference.

BioTrinity 2021 will be delivered live in a hybrid format at etc. venues Bishopsgate, London and via a dedicated virtual platform on Monday 21 & Tuesday 22 June in person, with the virtual platform available until Friday 25 June.

Actimed CEO Robin Bhattacherjee will present in-person an update on recent progress at 10:15 BST on Monday 21st June (day 1 of BioTrinity).  This will cover recent successful closing of the extended seed B funding round, the S-oxprenolol licensing agreement with US company Faraday Pharmaceuticals as well as clinical development plans for lead asset S-pindolol (ACM 001.1) in cancer cachexia.

For more information on the BioTrinity event please see BioTrinity Home.